Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 499-508

  Warzocha, K ^a   Salles, G ^a   Bienvenu, J ^a   Bastion, Y ^a   Dumontet, C ^a   Renard, N ^a   Neidhardt Berard, E M ^a   Coiffier, B ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; LACTATE DEHYDROGENASE; LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031037239     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.499     Document Type: Article

References (35)

1. Coiffier B, Lepage E: Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 74:558-564, 1989
2. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83:1165-1173, 1994
3. Shipp MA, Harrington DP, Anderson JR, et al.: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
4. Bastion Y, Coiffier B: Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 12:1340-1342, 1994
5. López-Guillermo A, Montserrat E, Bosch F, et al.: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
6. 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518-1527, 1989
7. Blay JY, Burdin N, Rousset F, et al.: Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor. Blood 82:2169-2174, 1993
8. Kurzrock R, Redman J, Cabanillas F, et al.: Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B-symptoms. Cancer Res 53:2118-2122, 1993
9. Raziuddin S, Sheikha A, Abu-Eshy S, et al.: Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer 73:2426-2431, 1994
10. Adami F, Guarini A, Pini M, et al.: Serum levels of tumor necrosis factor-α in patients with B-cell chronic lymphocytic leukaemia. Eur J Cancer 30A:1259-1263, 1994
11. Macia J, Gomez X, Perez B, et al.: Prognostic value of tumor necrosis factor in plasma of patients with chronic lymphoproliferative syndromes: preliminary results. Blood 84:989-991, 1994
12. Gruss HJ, Dolken G, Brach MA, et al.: The significance of serum levels of soluble 60kD receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia 7:1339-1343, 1993
13. Gruss HJ, Dower SK: Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 85:3378-3404, 1995
14. Cordingley FT, Hoffbrand AV, Heslop HE, et al.: Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1:969-971, 1988
15. Digel W, Stefanic M, Schoniger W, et al.: Tumor necrosis factor induces proliferation of neoplastic B-cells from chronic lymphocytic leukemia. Blood 73:1242-1246, 1989
16. Trentin L, Zambello R, Agostini C, et al.: Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood 81:752-758, 1993
17. Ruco LP, Pomponi D, Pigott R, et al.: Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and non-Hodgkin's lymphomas. Am J Pathol 137:1163-1169, 1990
18. Gibbons DL, Rowe M, Cope AP, et al.: Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Immunol 24:1879-1885, 1994
19. Mosialos G, Birkenbach M, Yalamanchili R, et al.: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399, 1995
20. De Togni P, Goellner J, Ruddle NH, et al.: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264:703-707, 1994
21. Matsumoto M, Mariathasan S, Nahm MH, et al.: Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 271:1289-1291, 1996
22. Salles G, Bienvenu J, Bastion Y, et al.: Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol 93:352-359, 1996
23. Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
24. Coiffier B, Gisselbrecht C, Herbrecht R, et al.: LNH-84: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
25. Roodman GD: TNF and hematopoiesis, in Beutler B (ed): Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York, NY, Raven, 1992, pp 117-129
26. Boussiotis VA, Nadler LM, Strominger JL, et al.: Tumor necrosis factor α is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA 91:7007-7011, 1994
27. Hsu SM, Waldron JW, Hsu PL, et al.: Cytokines in malignant lymphomas: Review and prospective evaluation. Hum Pathol 24:1040-1057, 1993
28. Balkwill FR: Tumour necrosis factor and cancer. Prog Growth Factor Res 4:121-137, 1992
29. Lindemann A, Ludwig WD, Oster W, et al.: High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood 73:880-884, 1989
30. Michalevicz R, Porat R, Vechoropoulos M, et al.: Restoration of in vitro hematopoiesis in B-chronic lymphocytic leukemia by antibodies to tumor necrosis factor. Leukemia Res 15:111-120, 1991
31. Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, et al.: Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α in response to autologous tumor stimulation. Blood 82:1204-1211, 1993
32. Qin Z, Blankenstein T: Tumor growth inhibition mediated by lymphotoxin: Evidence of B lymphocyte involvement in the antitumor response. Cancer Res 55:4747-4751, 1995
33. Lazenby AW, Roth JA, Owen-Schaub LB, et al.: IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin). Cytokine 4:479-487, 1992
34. Kimura K, Abe Y, Horiuchi A, et al.: Membrane-associated lymphotoxin-expressing lymphokine-activated killer cells up-regulate intercellular adhesion molecule-1 expression on target tumor cells in vitro. Cell Immunol 164:119-125, 1995
35. Grell M, Douni E, Wajant H, et al.: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802, 1995